Avalo Therapeutics Inc (AVTX) — Strategic Asset Allocation Index
Avalo Therapeutics Inc (AVTX) has a Strategic Asset Allocation Index of 41.1% as of March 2022. Strategic assets (PP&E of $2.60 Million plus long-term investments of $-) total $2.60 Million, measured against net assets of $6.34 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Avalo Therapeutics Inc Strategic Asset Allocation Index (2017–2021)
This chart shows how Avalo Therapeutics Inc's Strategic Asset Allocation Index has evolved across 5 annual periods from 2017 to 2021. As of March 2022, the index stands at 41.1%, representing strategic assets of $2.60 Million against net assets of $6.34 Million USD. Explore Avalo Therapeutics Inc cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Avalo Therapeutics Inc (2017–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Avalo Therapeutics Inc from 2017 to 2021, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Avalo Therapeutics Inc.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 11.7% | $2.69 Million | $2.69 Million | $- | $23.08 Million | ▲ +5.1 pp |
| 2020 | 6.5% | $1.61 Million | $1.61 Million | $- | $24.56 Million | ▼ -0.4 pp |
| 2019 | 6.9% | $1.45 Million | $1.45 Million | $- | $21.00 Million | ▲ +4.1 pp |
| 2018 | 2.8% | $586.51K | $586.51K | $- | $20.91 Million | ▲ +2.6 pp |
| 2017 | 0.2% | $44.61K | $44.61K | $- | $27.86 Million | — |